vTv Therapeutics cuts 65% of employees in shakeup; Freenome bags $300M in Series D to expand multiomics platform

vTv Therapeutics has decided to chop down its workforce by almost two-thirds.

The High Point, NC biotech announced Monday that it would pivot and now prioritize its lead program, the oral glucokinase activator TTP399, as it gears up for Phase III pivotal trials.

Click to view original post